How the FDA's priority review voucher program creates a financial incentive for developing psilocybin and other psychedelics as treatments — and which compounds have applied.
An FDA Priority Review Voucher (PRV) is a transferable certificate that lets any drug sponsor request a faster FDA review of a future application. Congress created traditional PRVs in 2007 to encourage companies to develop drugs for neglected tropical diseases and rare pediatric conditions that the market alone would not fund.
The mechanics are straightforward. A company earns a PRV by getting FDA approval for a qualifying drug — say, a treatment for a rare childhood disease. The company can then use that voucher on a separate, more commercially valuable drug application, or sell it to another company that wants the faster review.
Traditional PRVs cut the standard FDA review clock from 12 months to 6 months. In 2026, psychedelic companies received a newer version — the Commissioner's National Priority Voucher — that targets 1–2 month reviews. Both programs leave the approval standard unchanged.
Every month of FDA review time a drug spends in queue costs a company money and delays patient access. For a drug with peak annual sales of $1 billion, six months of early access is worth roughly $500 million in lost revenue — which is why companies pay up to $160 million on the secondary market for a voucher that saves those months. For psychedelic drugs, where patent clocks are already running, the same math applies.
The Commissioner's National Priority Voucher (CNPV) is a newer FDA pilot program that goes further than a traditional PRV by targeting a 1–2 month review instead of six months. The two programs work differently in important ways.
FDA Commissioner Marty Makary launched the CNPV pilot in June 2025. Instead of routing an application through the standard multi-office queue, CNPV reviews use a multidisciplinary team of physicians and scientists. The team pre-reviews submitted data and meets in a single one-day session — modeled on a hospital tumor board — to reach a decision. That format is why review time drops so dramatically.
| Feature | Traditional Priority Review Voucher (PRV) | Commissioner's National Priority Voucher (CNPV) |
|---|---|---|
| Review time target | 6 months (vs. 12-month standard) | 1–2 months |
| Review process | Standard multi-office queue, expedited | Multidisciplinary team, tumor-board style one-day meeting |
| Created by | Congress (2007, via statute) | FDA Commissioner (2025, pilot program) |
| Transferable / sellable | Yes — secondary market $100–160M in 2024–2025 | Pilot rules differ; transferability not yet established |
| Approval standard | Unchanged — safety and efficacy still required | Unchanged — same statutory and regulatory requirements |
| Psychedelic recipients | None confirmed as of June 2026 | Compass Pathways, Usona Institute, Transcend Therapeutics (April 2026) |
| When to choose | Useful if you want a sellable financial asset; works across any NDA | Better for fastest possible review; tied to executive-order-eligible compounds |
On April 24, 2026, FDA Commissioner Makary announced that FDA had issued Commissioner's National Priority Vouchers to three psychedelic drug programs — all holding Breakthrough Therapy designation and all targeting serious mental health conditions.
Compass Pathways received a CNPV for COMP360, its synthetic psilocybin formulation, for treatment-resistant depression (TRD). COMP360 had already met primary endpoints in two Phase 3 trials by early 2026, with effects lasting at least 26 weeks from one or two doses. Compass is targeting a rolling NDA submission in Q4 2026. With the CNPV, FDA could reach a decision within 1–2 months of that submission — meaning a possible approval decision in late 2026 or early 2027.
One detail rarely covered elsewhere: the CNPV pre-submission period runs approximately 60 days before the application clock starts. That means Compass must engage with the review team well before its NDA is formally filed — an earlier coordination burden most press coverage has not flagged.
Usona Institute, a Wisconsin-based nonprofit, received a CNPV for its psilocybin program targeting major depressive disorder (MDD). Usona's Phase 2 PSIL201 study, published in JAMA, showed a single dose produced a rapid, large, and sustained antidepressant effect. Usona's Phase 3 program (uAspire) is ongoing, and analysts expect an NDA no earlier than 2027–2028 — meaning the voucher speeds review once data are ready, but does not move the trial clock.
Transcend Therapeutics received a CNPV for TSND-201, a proprietary formulation of methylone, for PTSD. Methylone is an entactogen similar to MDMA but with a distinct pharmacological profile — it acts at monoamine transporters and does not bind the 5-HT2A receptor, so it is not hallucinogenic. FDA granted Breakthrough Therapy designation to TSND-201 in July 2025. Transcend is preparing a Phase 3 program for 2026. Otsuka Pharmaceutical is expected to acquire Transcend in 2026.
President Trump signed an executive order titled "Accelerating Medical Treatments for Serious Mental Illness" on April 18, 2026 — directing FDA to issue CNPVs to psychedelic drugs that hold Breakthrough Therapy designation for serious mental health conditions.
The order also directed the Drug Enforcement Administration to initiate scheduling reviews for compounds that complete Phase 3 trials, so that rescheduling can follow approval as fast as possible. It allocated $50 million through ARPA-H for federal-state research partnerships and directed FDA and DEA to create a Right to Try pathway for investigational psychedelic drugs — including ibogaine compounds.
Six days after the order — on April 24, 2026 — FDA announced the three vouchers. The speed of the awards reflects that the agency had already done most of the qualifying review under the existing CNPV pilot before the order was signed.
The order explicitly names ibogaine compounds in the Right to Try pathway it instructs FDA and DEA to create. Ibogaine holds enormous interest among veterans' advocacy groups for opioid addiction and PTSD. No ibogaine program received a CNPV in April 2026 — the compound does not yet have Breakthrough Therapy designation in the US — but the order places it in the same policy frame. See the Texas ibogaine bill guide for state-level movement.
The CNPV changes the FDA review clock, not the Phase 3 data clock. Understanding this distinction is the single most important thing for anyone tracking psilocybin approval.
Compass Pathways is the closest to an NDA filing. With two positive Phase 3 trials in hand and a CNPV in place, the company is on track for a late-2026 or early-2027 FDA decision on COMP360 for TRD. Usona's MDD program is likely 2027–2028, since its Phase 3 trial is still enrolling. MDMA-assisted therapy had its FDA advisory committee vote go against it in 2024; MDMA does not hold a CNPV and is on a separate track entirely.
One thing the CNPV does change: the pre-NDA engagement timeline. Under the tumor-board review model, FDA expects approximately 60 days of pre-submission interaction with the review team before the formal clock starts. That front-loads preparation work — companies need their entire dossier ready earlier than in a standard NDA track.
Traditional priority review vouchers traded at $100–160 million on the secondary market in 2024–2025. Bavarian Nordic sold one for $160 million in 2025 after winning approval for its chikungunya vaccine. Acadia Pharmaceuticals sold one for $150 million in late 2024. The record was $350 million, paid by AbbVie to United Therapeutics in 2015.
The value reflects pure time: a company with a blockbuster drug pays for early-entry advantage. A six-month faster review on a $2 billion annual drug is worth $1 billion in revenue, so $150 million for the voucher is a rational trade.
The Commissioner's National Priority Vouchers given to psychedelic companies are not traditional PRVs and do not currently operate on the same transferable-voucher secondary market. Their value lies in the 1–2 month review speed for the company that holds them, not in the ability to sell them for cash. This distinction matters for investors evaluating psychedelic biotech stocks and their pipeline timelines.
Psilocybin and methylone remain Schedule I controlled substances under the Controlled Substances Act as of June 2026. A CNPV does not change their scheduling, remove research restrictions, or legalize them for clinical use outside an approved trial.
FDA approval of a specific drug product — such as COMP360 — would trigger a separate DEA process to reschedule that compound. The April 2026 executive order directs DEA to begin reviewing relevant compounds when Phase 3 trials complete, which is designed to compress the gap between FDA approval and DEA rescheduling. But that gap has historically run 12–18 months, and it remains a separate administrative step.
Until a product is both approved by FDA and rescheduled by DEA, prescribers cannot legally dispense it — regardless of how fast FDA reviewed the application. Patients seeking legal access today should check the legal status by state tool and the full guide on what psychedelics are legal in the US.
FDA approval of a psilocybin drug product like COMP360 would make it legal for licensed healthcare providers to prescribe that specific formulation for its approved indication. It would not legalize personal use, home cultivation, or state licensed healing-center programs for non-approved uses. The patchwork of state laws — Colorado Proposition 122, Oregon Measure 109, and others — would continue to operate independently of federal approval. See our guide to where magic mushrooms are legal for the current state-by-state picture.
An FDA Priority Review Voucher (PRV) is a transferable certificate that lets the holder request a faster FDA review of any drug application — cutting the standard 10–12 month review to 6 months. The FDA's newer Commissioner's National Priority Voucher (CNPV) program compresses that further to 1–2 months. Three psychedelic programs — two psilocybin applications and one methylone application — received CNPVs in April 2026 under an executive order directing FDA to fast-track psychedelic drugs with Breakthrough Therapy designation.
Three programs received Commissioner's National Priority Vouchers (CNPVs) on April 24, 2026: Compass Pathways' synthetic psilocybin (COMP360) for treatment-resistant depression, Usona Institute's psilocybin for major depressive disorder, and Transcend Therapeutics' methylone (TSND-201) for PTSD. All three held FDA Breakthrough Therapy designation before receiving their vouchers.
Traditional priority review vouchers sold on the secondary market for roughly $100–160 million in 2024–2025. Bavarian Nordic sold one for $160 million in 2025; Acadia sold one for $150 million in 2024. The newer Commissioner's National Priority Vouchers issued for psychedelics are not yet transferable in the same way, but they compress review to 1–2 months rather than the standard 10–12 months.
No. A voucher speeds up FDA's review timeline, but it does not change the scientific or regulatory standards for approval. FDA must still find the drug safe and effective based on Phase 3 trial data. The voucher means the agency will review and decide faster — not that it will approve.
A traditional Priority Review Voucher shortens FDA's standard 12-month review to 6 months and can be sold on the secondary market for $100–160 million. The Commissioner's National Priority Voucher (CNPV) is a newer FDA pilot program that targets 1–2 month review using a multidisciplinary "tumor board" team approach. The CNPV was created by FDA Commissioner Makary in June 2025 and is what psychedelic companies received in April 2026.
Compass Pathways is targeting an NDA submission for COMP360 in Q4 2026 and a potential approval decision in late 2026 or early 2027, aided by the Commissioner's National Priority Voucher. Usona Institute's timeline is likely 2027–2028. Both timelines assume successful NDA submissions; the FDA voucher only shortens review time after the application is submitted.
Our legalization tracker follows FDA milestones, executive orders, state bills, and DEA scheduling actions — updated automatically. See where each compound stands right now.
Get FDA Priority Review Vouchers — Psychedelics updates
New votes, rules, court rulings, and access changes for FDA Priority Review Vouchers — Psychedelics — delivered when they happen.
← Back to all psychedelic laws
Suggest a tool, topic, or improvement that would make this site more useful.